IMO we're past the hiccups stage already.
NTI is a microcap.
It can't do everything on its own.
The less distraction and diversion of resources from the most promising indication the better.
ASD has excellent efficacy and safety.
ASD has huge unmet need.
ASD doesn't have an approved treatment.
I'd be happer if NTI pursued only ASD until ASD is either partnered or approved.
By all means go off on a tangent later.
Chart - NTI, page-139
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.4¢ |
Change
0.003(4.92%) |
Mkt cap ! $63.07M | |||
| Open | High | Low | Value | Volume |
| 6.3¢ | 6.4¢ | 6.1¢ | $80.43K | 1.276M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29383 | 6.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.5¢ | 110000 | 2 |
View Market Depth
| Last trade - 12.35pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.3¢ |
Change
0.003 ( 3.28 %) |
||||
| Open | High | Low | Volume | ||
| 6.3¢ | 6.4¢ | 6.2¢ | 354691 | ||
| Last updated 12.45pm 17/06/2024 ? | |||||
| NTI (ASX) Chart |
